Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

MedMira Inc V.MIR

Alternate Symbol(s):  MMIRF

MedMira Inc. is a Canada-based developer and manufacturer of Rapid Vertical Flow (RVF) diagnostics. The Company's tests provide hospitals, labs, clinics and individuals with instant disease diagnosis, such as human immunodeficiency virus (HIV), syphilis, hepatitis, and SARS-CoV-2, in three steps. The Company is engaged in the business of research, development and manufacturing of rapid diagnostics and technologies. Its research is focused on specific areas of the broader diagnostics market, namely the rapid, point-of-care, and in vitro sectors. Its tests are sold globally under the REVEAL, REVEALCOVID-19, Multiplo and Miriad brands. Based on its patented Rapid Vertical Flow Technology, the Company's rapid HIV test has regulatory approvals in Canada, the United States, China and the European Union. Its manufacturing facilities are located in Halifax, Nova Scotia, Canada. It provides access to its RVF Technology for researchers, developers, and biotech companies on a license basis.


TSXV:MIR - Post by User

Bullboard Posts
Post by nlegallon Jul 20, 2008 7:32pm
282 Views
Post# 15310898

It is possible

It is possible

From a pharmainsider1 on marketwatch.

Interesting read


Big Pharma has been in a recession for a few years. Many Research and Development and sales jobs have been cut. They are having problems developing new drugs. The "development cycle" is working against them as most of the blockbuster drugs they relied upon in the past are losing patent protection. There is not enough in the pipelines to replace them.

Additionally, they face the prospect of a Democratic Congress and a President Obama, who will try to nationalize the heathcare system.

Not a good environment for the intermediate term in Pharma.

But they are taking a page out of the book of the rest of the economy. They are moving jobs to China and India. There they can pay 1/4 the wages, take advantage of growing markets and reduce costs in the US (to prepare for drug price controls). Think China is bad at importing toys? Wait until they make all the drugs there. Baxter had problems/recalls of heparin made there recently. It is just the beginning.

"Investing" in the sector is more of a gamble. You can make money on smaller Biotech companies that happen to discover a new drug and/or are taken over by a large drug company. But, I would not be investing money in the standard Big Pharma stocks unless the PE was about 10 and all the major patent expirations were behind. For example, Pfizer trades at a forward PE of about 10, but they will lose 1/3 of their revenue when Lipitor losses patent protection in 2011. They don't appear to have anything in the pipeline to replace it. So, when evaluating the shares you need to realize the PE will not be 10, but rather much higher.

The article implies it is a good thing that Pharma will benefit from a weak dollar. Not exactly the kind of long-term business plan that makes for a good investment. I need to see increased revenues as they sell more product. And I need to see new Drugs to drive the revenue in the future

Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse